Mycophenolic acid
- Generic Name
- Mycophenolic acid
- Brand Names
- Myfortic
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20O6
- CAS Number
- 24280-93-1
- Unique Ingredient Identifier
- HU9DX48N0T
- Background
Mycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis. It was derived from Penicillium stoloniferum, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacroli...
- Indication
Mycophenolic acid is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. Mycophenolic acid is used in combination with cyclosporine and corticosteroids.
- Associated Conditions
- Kidney Transplant Rejection
- Associated Therapies
- -
Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients
- Conditions
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Seoul St. Mary's Hospital
- Target Recruit Count
- 234
- Registration Number
- NCT02036554
- Locations
- 🇰🇷
division of nephrology;Seoul St Mary's Hospital, Seoul, Korea, Republic of
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Rodolfo Alejandro
- Target Recruit Count
- 18
- Registration Number
- NCT01999361
- Locations
- 🇺🇸
Diabetes Research Institute, Miami, Florida, United States
A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 188
- Registration Number
- NCT01625377
- Locations
- 🇫🇷
Novartis Investigative Site, Villejuif, France
Crohn's Allogeneic Transplant Study
- Conditions
- Interventions
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT01570348
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
- Conditions
- Interventions
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01490723
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity
- Conditions
- Interventions
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT01473732
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 61
- Registration Number
- NCT01336296
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)
- Conditions
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Washington University, St. Louis, Missouri, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- Genovate Biotechnology Co., Ltd.,
- Target Recruit Count
- 40
- Registration Number
- NCT01261169
- Locations
- 🇨🇳
CGMH, Taoyuan County, Taiwan
Myfortic for the Treatment of Non-infectious Intermediate Uveitis
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- STZ eyetrial
- Target Recruit Count
- 44
- Registration Number
- NCT01092533
- Locations
- 🇩🇪
Charité Universitätsmedizin Berlin, Augenklinik, Berlin, Germany
🇩🇪Augenklinik der Ludwig-Maximilians-Universität München, München, Germany
🇩🇪Universitätsklinikum Heidelberg, Interdisziplinäres Uveitiszentrum, Heidelberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.